For Pediatricians & Specialists: Collaborative Cannabinoid Co-Management (2026) | CĒD Clinic
For Pediatricians & Specialists: Collaborative Cannabinoid Co-Management
A formal clinical bridge for general pediatricians, pediatric neurologists, child psychiatrists, and developmental specialists seeking safe, evidence-grounded cannabinoid co-management for treatment-refractory neurobehavioral conditions.
How does CĒD Clinic interface with a child’s primary care pediatrician and hospital specialists?
CĒD Clinic operates strictly as an adjunctive subspecialty practice. We do not replace the patient’s primary pediatric medical home, nor do we alter psychiatric or antiepileptic medications independently.
We assume complete clinical and legal responsibility for Massachusetts Cannabis Control Commission (CCC) regulatory documentation under 935 CMR 501, cannabinoid biochemical ratio design (CBD, CBDA, CBG, THC), therapeutic dose titration, CYP450 pharmacokinetic interaction monitoring, and routine hepatic safety surveillance — providing detailed consultation notes back to the primary care provider after every encounter.
The Institutional Policy Dilemma in Massachusetts Pediatric Medicine
Every week, primary pediatricians and specialists across Boston Children’s Hospital, Mass General Brigham, Tufts Children’s Hospital, and UMass Memorial encounter exhausted parents asking about cannabinoid therapeutics for autistic children suffering from self-injurious behavior (SIB), violent meltdowns, or intractable sleep fragmentation.
Most physicians face severe institutional barriers:
- Hospital System Prohibitions: Institutional bylaws at major academic medical centers frequently forbid staff clinicians from formally certifying cannabis due to federal Schedule I status and federal research funding concerns.
- Pharmacology & Dosing Education Gap: Medical schools and pediatric residency curricula have historically provided zero hours of instruction on the endocannabinoid system ($ECS$), leaving physicians uncomfortable with dosing, ratios, and terpene chemistry.
- CYP450 Liability Concerns: Legitimate clinical anxiety regarding competitive inhibition of cytochrome P450 enzymes (specifically $CYP3A4$, $CYP2C19$, and $CYP2C9$) when cannabinoids are combined with antiepileptics (Clobazam, Valproate) or antipsychotics (Risperidone, Aripiprazole).
CĒD Clinic solves this institutional dilemma. We serve as your trusted, board-certified referral partner. You retain full stewardship of the child’s primary medical care, while Dr. Benjamin Caplan oversees the specialized cannabinoid pharmacology and state regulatory compliance.
The Collaborative Division of Responsibilities
| Clinical Domain | Primary Pediatrician / Specialist | CĒD Clinic (Dr. Benjamin Caplan) |
|---|---|---|
| Primary Medical Home | Maintains ongoing well-child care, immunizations, diagnostic workups, and primary prescription management. | Serves strictly as adjunctive botanical subspecialist; coordinates all changes with the medical home. |
| 935 CMR 501 Certification | Signs the Second Physician Confirmation Form (if permitted by hospital policy) or provides diagnostic progress notes. | Performs primary CCC registration, issues physician certification, and manages annual re-evaluations. |
| Cannabinoid Pharmacokinetics | Informed via detailed CĒD Clinic progress notes of cannabinoid initiation, dosing, and product Certificate of Analysis (COA). | Calculates milligram-per-kilogram dosing, selects chemotype ratios (e.g., 20:1 CBD:THC, CBG, CBDA), and audits drug interactions. |
| Laboratory Surveillance | Collaborates on standard blood panels (CBC, ferritin, metabolic panels). | Orders and monitors targeted hepatic transaminases ($ALT/AST$) when high-dose CBD is co-administered with Valproate or Clobazam. |
MD-to-MD Direct Peer Consultation Request
Are you a pediatrician, neurologist, or child psychiatrist with questions regarding a complex refractory patient? Connect directly with Dr. Benjamin Caplan for peer-to-peer clinical discussion.
Evidence-Based Scientific Foundations & External Guidelines
The decision to trial cannabinoid therapeutics in treatment-refractory pediatric autism is grounded in a rapidly expanding corpus of peer-reviewed clinical trials and international registries:
- Randomized Double-Blind Trials: In a landmark study published in Neurology (Aran et al., 2019), whole-plant cannabinoid extracts achieved substantial behavioral disruption improvements in 61% of autistic children, with marked anxiety reduction in 39%.
- National Endocannabinoid Tone Deficits: Research in Molecular Autism (Karhson et al., 2018) demonstrated that circulating concentrations of the endogenous cannabinoid anandamide ($AEA$) are significantly lower in children with ASD compared to neurotypical controls ($p < 0.001$), supporting the clinical hypothesis of an innate endocannabinoid deficiency.
- Safety in Pediatric Epilepsy: The FDA approval of plant-derived Cannabidiol (Epidiolex) established rigorous pharmacokinetic parameters, demonstrating that cannabinoid therapy is safe when monitored for hepatic enzymes ($ALT/AST$) and serum levels of co-administered antiepileptics.
Refer a Patient or Schedule an MD Consultation
Partner with Dr. Benjamin Caplan to provide your patient's family with safe, legal, and rigorously monitored cannabinoid medicine. We ensure continuous clinical communication with your practice.